AlzChem Group Croissance future
Future contrôle des critères 3/6
AlzChem Group devrait augmenter ses bénéfices et son chiffre d'affaires de 12.6% et de 7.5% par an respectivement. Le BPA devrait croître de de 12.6% par an. Le rendement des capitaux propres devrait être 24% dans 3 ans.
Informations clés
12.6%
Taux de croissance des bénéfices
12.6%
Taux de croissance du BPA
| Chemicals croissance des bénéfices | 35.1% |
| Taux de croissance des recettes | 7.5% |
| Rendement futur des capitaux propres | 24.0% |
| Couverture par les analystes | Low |
| Dernière mise à jour | 11 Nov 2024 |
Mises à jour récentes de la croissance future
Recent updates
AlzChem Group's (ETR:ACT) Earnings May Just Be The Starting Point
Nov 14
AlzChem Group AG's (ETR:ACT) Shares Leap 26% Yet They're Still Not Telling The Full Story
Oct 27When Should You Buy AlzChem Group AG (ETR:ACT)?
Oct 18AlzChem Group (ETR:ACT) Has A Pretty Healthy Balance Sheet
Sep 07A Look At The Intrinsic Value Of AlzChem Group AG (ETR:ACT)
Jun 04AlzChem Group's (ETR:ACT) Earnings Seem To Be Promising
May 08Shareholders Will Probably Hold Off On Increasing AlzChem Group AG's (ETR:ACT) CEO Compensation For The Time Being
May 01AlzChem Group's (ETR:ACT) Upcoming Dividend Will Be Larger Than Last Year's
Apr 26Is AlzChem Group (ETR:ACT) A Risky Investment?
Apr 11AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.20
Mar 29The Market Lifts AlzChem Group AG (ETR:ACT) Shares 26% But It Can Do More
Mar 07Why AlzChem Group AG (ETR:ACT) Could Be Worth Watching
Nov 01Is There An Opportunity With AlzChem Group AG's (ETR:ACT) 42% Undervaluation?
Oct 12AlzChem Group (ETR:ACT) Is Increasing Its Dividend To €1.05
May 06AlzChem Group AG's (ETR:ACT) CEO Compensation Is Looking A Bit Stretched At The Moment
May 05AlzChem Group (ETR:ACT) Will Pay A Larger Dividend Than Last Year At €1.05
Apr 05AlzChem Group (ETR:ACT) Is Increasing Its Dividend To €1.05
Mar 04AlzChem Group (ETR:ACT) Is Paying Out A Larger Dividend Than Last Year
Apr 24AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.00
Mar 29AlzChem Group (ETR:ACT) Has Announced That It Will Be Increasing Its Dividend To €1.00
Feb 27AlzChem Group (ETR:ACT) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Nov 23Are Investors Undervaluing AlzChem Group AG (ETR:ACT) By 46%?
Jun 10At €24.50, Is AlzChem Group AG (ETR:ACT) Worth Looking At Closely?
Apr 07AlzChem Group AG (ETR:ACT) Is Yielding 3.0% - But Is It A Buy?
Mar 23AlzChem Group AG's (ETR:ACT) Intrinsic Value Is Potentially 32% Above Its Share Price
Mar 10Is AlzChem Group AG's (ETR:ACT) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Feb 24Our Take On The Returns On Capital At AlzChem Group (ETR:ACT)
Feb 11
Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2026 | 636 | 61 | 48 | 108 | 4 |
| 12/31/2025 | 596 | 55 | 33 | 134 | 4 |
| 12/31/2024 | 566 | 52 | 51 | 92 | 4 |
| 9/30/2024 | 564 | 50 | 82 | 103 | N/A |
| 6/30/2024 | 555 | 46 | 76 | 97 | N/A |
| 3/31/2024 | 546 | 39 | 73 | 96 | N/A |
| 12/31/2023 | 546 | 35 | 52 | 73 | N/A |
| 9/30/2023 | 533 | 30 | 25 | 55 | N/A |
| 6/30/2023 | 554 | 28 | 24 | 53 | N/A |
| 3/31/2023 | 570 | 30 | -15 | 12 | N/A |
| 12/31/2022 | 550 | 30 | -33 | -4 | N/A |
| 9/30/2022 | 534 | 29 | -25 | 4 | N/A |
| 6/30/2022 | 487 | 28 | -28 | 0 | N/A |
| 3/31/2022 | 454 | 27 | 3 | 29 | N/A |
| 12/31/2021 | 429 | 28 | 14 | 43 | N/A |
| 9/30/2021 | 420 | 27 | 11 | 40 | N/A |
| 6/30/2021 | 406 | 26 | 34 | 63 | N/A |
| 3/31/2021 | 397 | 23 | 14 | 48 | N/A |
| 12/31/2020 | 386 | 20 | 20 | 49 | N/A |
| 9/30/2020 | 370 | 16 | 10 | 52 | N/A |
| 6/30/2020 | 389 | 17 | 11 | 53 | N/A |
| 3/31/2020 | 387 | 17 | 20 | 54 | N/A |
| 12/31/2019 | 385 | 18 | 2 | 44 | N/A |
| 9/30/2019 | 389 | 19 | 2 | 42 | N/A |
| 6/30/2019 | 380 | 18 | -18 | 22 | N/A |
| 3/31/2019 | 380 | 20 | -20 | 33 | N/A |
| 12/31/2018 | 383 | 23 | -5 | 35 | N/A |
| 9/30/2018 | 380 | 22 | 12 | 24 | N/A |
| 6/30/2018 | 398 | 32 | N/A | 31 | N/A |
| 3/31/2018 | 364 | 21 | N/A | 23 | N/A |
| 12/31/2017 | 361 | 20 | N/A | 31 | N/A |
| 9/30/2017 | 356 | 22 | N/A | 31 | N/A |
| 12/31/2016 | 333 | 15 | N/A | 33 | N/A |
| 9/30/2016 | 331 | 12 | N/A | 39 | N/A |
| 12/31/2015 | 329 | 15 | N/A | 30 | N/A |
| 12/31/2014 | 298 | 14 | N/A | 18 | N/A |
| 12/31/2013 | 302 | 17 | N/A | 16 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de ACT ( 12.6% par an) est supérieure au taux d'épargne ( 1% ).
Bénéfices vs marché: Les bénéfices de ACT ( 12.6% par an) devraient croître plus lentement que le marché German ( 20.8% par an).
Croissance élevée des bénéfices: Les bénéfices de ACT devraient augmenter, mais pas de manière significative.
Chiffre d'affaires vs marché: Le chiffre d'affaires de ACT ( 7.5% par an) devrait croître plus rapidement que le marché German ( 5.6% par an).
Croissance élevée des revenus: Le chiffre d'affaires de ACT ( 7.5% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de ACT devrait être élevé dans 3 ans ( 24 %)